Skip to main content
. 2023 Apr 11;28(8):3356. doi: 10.3390/molecules28083356

Table 2.

B7-H3-targeting mAb-based anti-tumor agents in clinical studies involving PSTs. The table shows the studies on extracranial PSTs as well as the studies involving their metastases in the CNS.

Study/Phase
(Reference)		 Agent/Drug Route of Administration Study Participants Status
NCT00089245
Phase I
[115]		 131I-labeled 8H9 mAbs 1 Intrathecal Patients with refractory, recurrent, or advanced CNS or leptomeningeal cancer Active, not recruiting
NCT03275402
Phase II/III
[116] 		131I-labeled 8H9 mAbs Intraventricular Patients with NB metastatic to CNS or with leptomeningeal metastases Recruiting
NCT02982941
Phase I
[117]		 Enoblituzumab 2 Intravenous Patients with relapsed or refractory NB, RMS, OS, ES, WT, or DSRCT Completed
NCT05064306
N/A
[118]		 131I-omburtamab Intraventricular Patients with solid tumors and CNS/leptomeningeal involvement Available
NCT04022213
Phase II
[119]		 131I-omburtamab Intraperitoneal DSRCT and other tumors with peritoneal involvement Recruiting

1 8H9 mAb—a B7-H3-targeting mAb also known as omburtamab. 2 Enoblituzumab—a B7-H3-targeting mAb also known as MGA271. Abbreviations: B7-H3: B7 homolog 3; mAb: monoclonal antibody; PSTs: pediatric solid tumors; CNS: the central nervous system; NB: neuroblastoma; RMS: rhabdomyosarcoma; OS: osteosarcoma; ES: Ewing sarcoma; WT: Wilms tumor; DSRCT: desmoplastic small round cell tumor.